SOUTH SAN FRANCISCO, Calif. – Fluidigm Corporation (NASDAQ:FLDM) today announced it is affirming its previously disclosed 2011 financial outlook.

In its August 9, 2011 earnings release, Fluidigm disclosed that for the full year 2011, year-over-year product revenue growth was projected to be at the high end of a range of 27% to 30% and revenue from grants and collaborations was projected to be around $2.0 million. Nothing has come to Fluidigm’s attention that would cause it to change such guidance.

Fluidigm has elected to make this announcement given concerns regarding research funding levels, overall market conditions and recent announcements by other life science tools companies. Fluidigm does not expect to make future announcements regarding its financial outlook outside of its regularly-scheduled quarterly earnings calls. Fluidigm will conduct its next quarterly earnings call in early November, when it will present more detailed financial information and a business update.

About Fluidigm

Fluidigm (NASDAQ: FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.